Adding topiramate to valproate therapy may cause reversible hepatic failure

Area of Science:

• Neurology
• Hepatology
• Clinical Pharmacology

Background:

• Pharmacoresistant partial epilepsy requires combination antiepileptic drug (AED) therapy.
• Valproate is a commonly used AED with known potential for hepatotoxicity.
• Topiramate is another AED used for epilepsy management.

Observation:

• A 51-year-old female patient with pharmacoresistant epilepsy tolerated valproate monotherapy and combinations with other AEDs well.
• The patient developed symptoms and signs of reversible hepatic failure specifically when treated with a combination of valproate and topiramate.
• Hepatic symptoms resolved completely after the discontinuation of valproate (VPA).

Findings:

• This case highlights a potential drug interaction between valproate and topiramate leading to hepatotoxicity.
• The combination of valproate and topiramate appears to pose a significant risk for liver failure, even in patients who tolerate valproate with other AEDs.
• The observed hepatic failure was reversible upon withdrawal of valproate.

Implications:

• Clinicians should exercise caution when prescribing combination therapy with valproate and topiramate, especially in patients with epilepsy.
• This case underscores the importance of monitoring liver function in patients receiving combined valproate and topiramate therapy.
• Further research may be warranted to elucidate the mechanisms underlying this potential drug-induced liver injury.